GlassScriptPhysician profile
Laura Leblanc
NPI 1679589758
$5,580.69
in general payments reported to CMS, 2019-2025
30 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $786 · 2023: $1,096 · 2024: $1,938 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,373 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,373.14 |
| Education | $290.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.44 | 2021-2025 | |
| Janssen Biotech, INC. | $1,451.98 | 2022-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.96 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $281.25 | 2022-2025 | Livdelzi |
| Genzyme Corporation | $277.16 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $257.88 | 2024-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $134.27 | 2022-2025 | Entyvio, Gattex |
| Merit Medical Systems INC | $129.50 | 2025 | Esophyx |
| Celgene Corporation | $116.56 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $115.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Csl Behring | $101.33 | 2022-2023 | Privigen, Hizentra |
| Genentech USA, INC. | $98.62 | 2023-2024 | Ocrevus |
| Pfizer INC. | $96.79 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $90.51 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $82.84 | 2024 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $77.08 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $71.42 | 2023-2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.26 | 2023-2024 | Cyltezo |
| Olympus America INC. | $34.63 | 2023-2025 | Visiglide, Endoclot Phs |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Alexion Pharmaceuticals, INC. | $27.41 | 2024 | Ultomiris |
| Acorda Therapeutics, INC | $27.26 | 2023 | Inbrija |
| Boston Scientific Corporation | $27.12 | 2021 | |
| Medtronic, INC. | $25.54 | 2022 | |
| Ge Healthcare | $19.89 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.20 | 2022 | |
| Acadia Pharmaceuticals INC | $18.69 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.52 | 2023 | Ocaliva |
| Abbott Laboratories | $17.30 | 2022 | |
| Celltrion USA INC. | $14.07 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.